Shahina Mukadam, Independent Market Expert told CNBC-TV18, "Sun Pharmaceutical Industries' prospects look good. Mohali is a very important plant for them especially with Halol going through problems, continuing the problems. I think definitely over FY18 and FY19 there are big products lined up and the company once it clears this USFDA hurdle for the rest of its plants should do much better."
"Its valuations after the sharp corrections we have seen in the last one and a half year is now just about 18 times one year forward which makes it decent even in terms of valuations, so definitely hold the stock Sun Pharma," he added.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
